Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy.
Due to its low level of nephrotoxicity and capacity to harness tolerogenic pathways, sirolimus (SRL) has been proposed as an alternative to calcineurin inhibitors in transplantation. The exact mechanisms underlying its unique immunosuppressive profile in humans, however, are still not well understood. In the current study, we aimed to depict the in vivo effects of SRL in comparison with cyclosporin A (CSA) by employing gene expression profiling and multiparameter flow cytometry on blood cells collected from stable kidney recipients under immunosuppressant monotherapy. SRL recipients displayed an increased frequency of CD4 + CD25highFoxp3 + T cells. However, this was accompanied by an increased number of effector memory T cells and by enrichment in NFkB-related pro-inflammatory expression pathways and monocyte and NK cell lineage-specific transcripts. Furthermore, measurement of a transcriptional signature characteristic of operationally tolerant kidney recipients failed to detect differences between SRL and CSA-treated recipients. In conclusion, we show here that the blood transcriptional profile induced by SRL monotherapy in vivo does not resemble that of operationally tolerant recipients and is dominated by innate immune cells and NFkB-related pro-inflammatory events. These data provide novel insights on the complex effects of SLR on the immune system in clinical transplantation.
Institut National de Santé Et de Recherche Médicale INSERM U643, and Institut de Transplantation Et de Recherche en Transplantation ITERT, Nantes, F-44093 France. sophie.brouard@univ-nantes.fr
S
S
Brouard
I
I
Puig-Pey
J-J
JJ
Lozano
A
A
Pallier
C
C
Braud
M
M
Giral
M
M
Guillet
M C
MC
Londoño
F
F
Oppenheimer
J M
JM
Campistol
J-P
JP
Soulillou
A
A
Sanchez-Fueyo
D018791:CD4 Lymphocyte Count; D016572:Cyclosporine / Q000627:therapeutic use*; D005434:Flow Cytometry; D020869:Gene Expression Profiling; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D010641:Phenotype; D020123:Sirolimus / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D020123:Sirolimus